m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00128)
Target Name microRNA 23a (MIR23A)
Synonyms
MIR23A; MIRN23A; hsa-mir-23a
    Click to Show/Hide
Gene Name MIR23A
Chromosomal Location 19p13.12
Family MicroRNA MIR23 family
Gene ID 407010
HGNC ID
HGNC:31605
miRBase ID
MI0000079
Ensembl Gene ID
ENSG00000207980
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MIR23A can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/microRNA 23a (MIR23A) Cluster-MXI1 Feedback Circuit in Glioma.
Responsed Disease Glioma ICD-11: 2A00.0
 Disease Info 
Responsed Drug Temozolomide Approved
 Drug Info 
In-vitro Model A-172 Glioblastoma Homo sapiens CVCL_0131
HEK293T Normal Homo sapiens CVCL_0063
U251 (Fibroblasts or fibroblast like cells)
U87 (A primary glioblastoma cell line)
In-vivo Model Previously prepared U87 cells (5 × 106 cells, 60 uL) stably infected with miRNA were injected subcutaneously in the right flank of the mice, whereas control U87 cells infected with empty vector were injected in the left flank.
Brain cancer [ICD-11: 2A00]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/microRNA 23a (MIR23A) Cluster-MXI1 Feedback Circuit in Glioma.
Responsed Disease Glioma [ICD-11: 2A00.0]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Responsed Drug Temozolomide Approved
 Drug Info 
In-vitro Model A-172 Glioblastoma Homo sapiens CVCL_0131
HEK293T Normal Homo sapiens CVCL_0063
U251 (Fibroblasts or fibroblast like cells)
U87 (A primary glioblastoma cell line)
In-vivo Model Previously prepared U87 cells (5 × 106 cells, 60 uL) stably infected with miRNA were injected subcutaneously in the right flank of the mice, whereas control U87 cells infected with empty vector were injected in the left flank.
Temozolomide [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/microRNA 23a (MIR23A) Cluster-MXI1 Feedback Circuit in Glioma.
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Responsed Disease Glioma ICD-11: 2A00.0
 Disease Info 
In-vitro Model A-172 Glioblastoma Homo sapiens CVCL_0131
HEK293T Normal Homo sapiens CVCL_0063
U251 (Fibroblasts or fibroblast like cells)
U87 (A primary glioblastoma cell line)
In-vivo Model Previously prepared U87 cells (5 × 106 cells, 60 uL) stably infected with miRNA were injected subcutaneously in the right flank of the mice, whereas control U87 cells infected with empty vector were injected in the left flank.
References
Ref 1 FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma. Cancer Res. 2020 Sep 15;80(18):3945-3958. doi: 10.1158/0008-5472.CAN-20-0132. Epub 2020 Jul 17.